ClinicalTrials.gg

Program

Chikungunya vaccine

Also written as “VLA1553”, “VLA1553 full dose” and “VLA1553 half dose”.

Its studies are mostly in Chikungunya Fever, led by Valneva.

Furthest: phase 3, since Sep 4, 20206 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valneva61 open or runningphase 3since Sep 4, 2020Dec 12, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2017First study: phase 1 study in Chikungunya FeverFirst studyNCT03382964 · 120 enrolled · United States
  2. Sep 4, 2020Phase 3 study in Chikungunya FeverNCT04546724 · 4,128 enrolled · United States
  3. Apr 6, 2021Phase 3 study in Chikungunya FeverNCT04838444 · 363 enrolled · United States
  4. Mar 29, 2023Phase 3 study in Chikungunya FeverNCT06028841
  5. Oct 24, 2023Phase 2 study in Chikungunya FeverNCT06106581 · 304 enrolled · Dominican Republic, Honduras
  6. Aug 13, 2025Phase 3 study in Chikungunya FeverNCT07133178

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07133178Chikungunya Fever3WithdrawnDec 20260
NCT06106581Chikungunya Fever · Dominican Republic, Honduras2CompletedJul 31, 2024304
NCT06028841Chikungunya Fever3WithdrawnAug 27, 20240
NCT04838444Chikungunya Fever · United States3Active, not recruitingMar 3, 2023363
NCT04546724Chikungunya Fever · United States3CompletedMay 19, 20214,128
NCT03382964Chikungunya Fever · United States1CompletedJul 13, 2018120

How it is read

Names in the registry

  • “VLA1553”, 5 entries
  • “VLA1553 full dose”, 1 entry
  • “VLA1553 half dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.